There really hasn't been anything for patients in between
For generations, patients with worn and aching knees have faced a stark binary: endure the pain or surrender to major surgery. A procedure called genicular artery embolization, developed in Japan and now gaining traction in the United States, is quietly rewriting that calculus — offering a minimally invasive middle path that targets the inflammation driving chronic osteoarthritis pain. In doing so, it raises a broader question about how medicine might reimagine the space between resignation and the operating table.
- Millions of osteoarthritis patients are trapped between treatments that no longer work and a major surgery they are not ready to face — GAE is emerging as the option that fills that void.
- The procedure threads a catheter to the knee's blood supply and releases microscopic beads to starve inflamed tissue, all within two hours and without an overnight hospital stay.
- Early results are striking: roughly 70% of patients report pain cut in half or more, with studies tracking relief out to four years and U.S. data confirming durability at the two-year mark.
- The FDA granted GAE breakthrough device status in 2021, and active clinical trials are now probing how deeply the procedure alters the joint's inflammatory environment — not just its blood flow.
- Researchers are already looking beyond the knee, testing whether the same logic might relieve frozen shoulder, tennis elbow, and plantar fasciitis — potentially reshaping how medicine treats the entire spectrum of musculoskeletal pain.
Cynthia Schraf-Fletcher, 74, had already been through one total knee replacement when her other knee began to fail her. Facing the prospect of a second major surgery, she chose a newer path: genicular artery embolization, or GAE. Nearly a year on, she gardens again, rides a stationary bike, and describes the pain relief as rivaling what she got from her full replacement — without the trauma of going under the knife.
GAE operates on a precise principle. Chronic knee pain from osteoarthritis is fed by inflammation, and inflammation depends on blood flow. An interventional radiologist makes a small incision near the groin, guides a catheter through the femoral artery to the genicular vessels wrapping around the knee, and releases microscopic beads that block blood flow to the abnormal tissue driving the pain. The procedure takes one to two hours. Patients go home the same day.
Dr. Leigh Casadaban of the University of Colorado Anschutz School of Medicine describes GAE as filling a long-standing gap in orthopedic care — the empty space between physical therapy and steroid injections on one end, and total joint replacement on the other. About 70% of patients see their pain scores cut in half or better, with Japanese studies showing sustained improvement at four years and U.S. data confirming durable relief at two. Casadaban believes the procedure may be doing more than blocking vessels — it may be actively reshaping the joint's inflammatory environment.
Patients with mild to moderate osteoarthritis tend to respond best, though those with more advanced disease can still benefit. Two clinical trials are currently underway at Casadaban's institution. And with the procedure holding FDA breakthrough device status since 2021, researchers are beginning to ask whether the same approach might work for frozen shoulder, tennis elbow, and plantar fasciitis — expanding a treatment logic that, for now, has only one approved address: the knee.
Cynthia Schraf-Fletcher, 74, had already endured one total knee replacement. When her other knee began to fail her—the pain making even simple tasks like gardening feel like a negotiation with her own body—she faced a choice that many people with worn joints dread: go under the knife again, or live with the ache. She chose a different path, one that didn't exist in any meaningful way just a few years ago.
She underwent a procedure called genicular artery embolization, or GAE. Nearly a year later, she describes the results as remarkable. The pain relief rivals what she got from her full replacement surgery, but without the trauma of major surgery. She gardens now. She rides a stationary bike. "I couldn't be more pleased," she says.
GAE works on a simple principle: chronic knee pain from osteoarthritis is often driven by inflammation, and inflammation needs blood flow. The procedure, developed in Japan just over a decade ago, targets that blood supply with precision. An interventional radiologist makes a small incision near the groin, threads a catheter through the femoral artery, and guides it to the genicular arteries that wrap around the knee. Using X-ray imaging and contrast dye as a map, the doctor releases microscopic beads that block blood flow to the abnormal vessels feeding the inflamed tissue. The whole thing takes one to two hours. Patients go home the same day.
Dr. Leigh Casadaban, an assistant professor of radiology at the University of Colorado Anschutz School of Medicine, has been watching this treatment fill a gap that has long existed in orthopedic care. "For treating osteoarthritis in the knees, we often think of medications, physical therapy, maybe a steroid injection, and then on the far end of the spectrum is a total knee replacement," he says. "There really hasn't been anything for patients in between." GAE is that middle ground—for people who have exhausted conservative options but aren't ready, or willing, to have their joint replaced.
The early data is encouraging. About 70 percent of patients see their pain scores cut in half or better. Some report no pain at all. The relief appears to last. Japanese studies tracking patients for four years show sustained improvement. In the United States, where the procedure has gained FDA breakthrough device status since 2021, two-year data tells a similar story: if you respond well to GAE, the pain relief holds. Casadaban theorizes that the procedure is doing something deeper than just blocking blood vessels—that it's actually modifying the inflammatory environment inside the joint itself.
People with mild to moderate osteoarthritis tend to benefit most. Those with more advanced disease can still have the procedure, though the effects tend to be less durable. Casadaban is currently running two clinical trials at his institution, one examining changes in knee fluid after GAE, another testing a temporary arterial blocking device called Nexsphere-F.
The procedure's success has researchers thinking bigger. Osteoarthritis affects millions of people and can strike almost any joint. Casadaban and others are beginning to explore whether GAE might work for frozen shoulder, tennis elbow, plantar fasciitis—the whole landscape of painful musculoskeletal conditions that currently offer patients the same limited menu: manage it, inject it, or cut it out. For now, the knee remains the only approved target. But the door is opening.
Citações Notáveis
For treating osteoarthritis in the knees, we often think of medications, physical therapy, maybe a steroid injection, and then on the far end of the spectrum is a total knee replacement. There really hasn't been anything for patients in between.— Dr. Leigh Casadaban, assistant professor of radiology at University of Colorado Anschutz School of Medicine
I couldn't be more pleased. Everyday activities such as gardening and riding a stationary bicycle are far more enjoyable because of the reduction in pain.— Cynthia Schraf-Fletcher, 74, patient who underwent GAE
A Conversa do Hearth Outra perspectiva sobre a história
Why does blocking blood vessels to an inflamed knee actually reduce pain? That seems counterintuitive—doesn't tissue need blood?
It does, but the abnormal blood vessels feeding the inflammation are part of the problem. They're not there to nourish healthy tissue. They're feeding the inflammatory response itself. By cutting off that supply, you're starving the inflammation, not the joint.
And this lasts for years? How is that possible if you're just blocking vessels?
That's the question Casadaban is trying to answer. The theory is that by reducing inflammation acutely, you're interrupting a cycle. The joint environment changes. It's not just a temporary fix—something in the joint itself seems to reset.
What about the people it doesn't work for? The 30 percent?
They tend to be the ones with very advanced disease, where the cartilage is almost gone. At that point, the inflammation is a symptom of deeper structural failure. You can't block your way out of that.
So this really is a middle option—not conservative enough to ignore, not drastic enough to be surgery.
Exactly. For someone like Schraf-Fletcher, who'd already had one replacement and knew what that cost, GAE was a chance to buy years of function without another major operation.
What happens if it stops working? Can you do it again?
That's still being studied. But yes, theoretically you could repeat it. That's part of what makes it attractive—it's not a one-shot, all-or-nothing decision like replacement surgery.